Answers are grounded in this paper and cite their sources.
Cystic fibrosis (CF) treatment has increasingly focused on highly effective modulators. Despite measurable benefits of modulators, there is little guidance for CF care team members on providing education and support to patients regarding initiation of these therapies. We aimed to explore patient, caregiver, and clinician perceptions of modulators and influences on decisions about starting cystic fibrosis transmembrane regulator (CFTR) modulators.
No takes yet. Share an insight, caveat, or question.
Landess et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: